Disorders of Sexual Development (DSD)

Overview & Terminology

• Definition: Discrepancy among chromosomal, gonadal, and genital sex.
• Nomenclature: Replaces historical, stigmatizing terms "intersex," "pseudohermaphrodite," and "hermaphrodite".
• Incidence: Approximately 1 in 4,000 live births. Rises significantly if all hypospadias and cryptorchidism cases included.
• Pathogenesis: Disruption in complex endocrine, paracrine, and autocrine signaling networks directing fetal gonadal development.

Normal timeline of fetal sexual differntiation

Bipotential Phase (Weeks 4-6)

Male Differentiation: Testis & Genitalia

Female Differentiation: Ovary & Genitalia

Embryology & Normal Sexual Differentiation

Bipotential Gonad Phase

• Occurs between 4-6 weeks gestation.
• Germ cells migrate from hindgut celomic epithelium to gonadal ridge.
• Requires specific transcription factors for somatic cell development: WT1, SF1 (NR5A1), GATA4, CBX2, EMX2, LIM1.
• Pluripotent state maintains genes poised for activation/repression of male/female pathways.

Testicular Differentiation (46,XY)

• Initiated at 6-7 weeks by SRY gene on Y chromosome.
• SRY triggers SOX9 expression, crucial for Sertoli cell differentiation.
• Testis secretes two key hormones:
  • Anti-Müllerian Hormone (AMH): Secreted by Sertoli cells. Induces Müllerian duct regression.
  • Testosterone: Secreted by Leydig cells (stimulated by placental hCG). Stabilizes Wolffian ducts (vas deferens, epididymis, seminal vesicles).
• Dihydrotestosterone (DHT): Converted from testosterone via 5α-reductase type 2 in target tissues. Drives external male virilization (phallic growth, labioscrotal fusion, testicular descent).
• Insulin-like factor 3 (INSL3): Secreted by Leydig cells. Required for transabdominal testicular descent.

Ovarian Differentiation (46,XX)

• Independent of SRY.
• Driven by ovary-specific genes: WNT4, RSPO1, FOXL2, DAX1 (NR0B1).
• WNT4 and DAX1 suppress androgen synthesis and repress the testicular pathway.
• Absence of AMH permits Müllerian duct differentiation into fallopian tubes, uterus, upper vagina.
• Absence of androgens leads to Wolffian duct regression and female external genitalia differentiation (lower vagina, labia, clitoris).

Classification of Disorders of Sex Development

Molecular Genetics & Specific Etiologies

46,XX DSD (Virilized Female)

Characterized by female internal genitalia (uterus, ovaries present) and virilized external genitalia.

Fetal Androgen Excess (Congenital Adrenal Hyperplasia)

• 21-Hydroxylase Deficiency (CYP21A2):
  • Most common cause of 46,XX DSD.
  • Autosomal recessive.
  • Decreased cortisol/aldosterone -> Increased ACTH -> Adrenal hyperplasia -> Massive androgen overproduction.
  • Phenotype ranges from mild clitoromegaly to complete penile urethra.
  • Diagnosis: Markedly elevated 17-OH Progesterone (17-OHP).
• 11β-Hydroxylase Deficiency (CYP11B1):
  • Autosomal recessive. ~5% of CAH cases.
  • Virilization plus hypertension/hypokalemia (due to elevated 11-deoxycorticosterone).
  • Diagnosis: Elevated 11-deoxycortisol and 11-deoxycorticosterone.
• 3β-Hydroxysteroid Dehydrogenase Deficiency (HSD3B2):
  • Impairs conversion of Δ5 to Δ4 steroids.
  • Mild virilization in females (elevated DHEA).
  • Salt-wasting crisis.
• P450 Oxidoreductase (POR) Deficiency:
  • Essential electron donor for CYP21, CYP17, aromatase.
  • Virilization of XX fetus via alternative "backdoor" DHT synthesis pathway.
  • Associated with Antley-Bixler syndrome (craniosynostosis, radiohumeral synostosis).

Fetoplacental & Maternal Androgen Excess

• Placental Aromatase Deficiency (CYP19A1):
  • Impaired conversion of fetal androgens to estrogens.
  • Marked maternal virilization during pregnancy.
  • Female fetus born with labioscrotal fusion and clitoromegaly.
• Maternal Tumors: Luteoma of pregnancy, arrhenoblastoma, Krukenberg tumors.
• Iatrogenic: Maternal ingestion of progestational/androgenic drugs.

Disorders of Gonadal Development

• 46,XX Testicular DSD (XX Male):
  • SRY gene translocated to X chromosome during paternal meiosis (90% of cases).
  • Normal male external genitalia; small azoospermic testes.
  • SRY-negative cases (10%) linked to SOX9 duplication or RSPO1 mutation.
• Ovotesticular DSD (True Hermaphrodite):
  • Presence of both ovarian and testicular tissue (often ovotestis).
  • Most common karyotype is 46,XX.
  • External genitalia variable; asymmetrical development common.

46,XY DSD (Undervirilized Male)

Characterized by male karyotype with ambiguous or complete female external genitalia.

Disorders of Testicular Differentiation (Gonadal Dysgenesis)

• Complete failure leads to female phenotype (Swyer syndrome). Partial failure leads to genital ambiguity.
• High risk of gonadoblastoma in dysgenetic intra-abdominal testes.
• WT1 Mutations: Denys-Drash syndrome (nephropathy, Wilms tumor, ambiguous genitalia). Frasier syndrome (focal segmental glomerulosclerosis, XY sex reversal, gonadoblastoma).
• SOX9 Mutations: Campomelic dysplasia (short-limbed dwarfism, bowed femora, cleft palate). 75% show complete male-to-female sex reversal.
• SF1 (NR5A1) Mutations: Adrenal insufficiency combined with 46,XY gonadal dysgenesis and Mullerian persistence.
• DHH (Desert Hedgehog): Gonadal dysgenesis with minifascicular polyneuropathy.
• SRY Mutations: Responsible for 15-20% of XY gonadal dysgenesis cases. Prevents DNA-binding/bending.
• Testicular Regression Syndrome (Vanishing Testes): Normal external genitalia, absent testes. In utero ischemic insult post-differentiation.

Disorders of Androgen Synthesis

• Congenital Lipoid Adrenal Hyperplasia (StAR deficiency): Defective cholesterol conversion. Complete female phenotype in XY. Salt-wasting.
• 17α-Hydroxylase/17,20-Lyase Deficiency (CYP17A1): Blocks synthesis of DHEA/androstenedione. Female/ambiguous genitalia. Hypertension and hypokalemia.
• 17β-Hydroxysteroid Dehydrogenase Type 3 Deficiency (HSD17B3): Impairs conversion of androstenedione to testosterone. Female external genitalia with blind vaginal pouch, but Wolffian structures present. Massive virilization at puberty due to extratesticular conversion.
• 5α-Reductase Type 2 Deficiency (SRD5A2): Impaired conversion of T to DHT. Ambiguous genitalia (pseudovaginal perineoscrotal hypospadias). Severe pubertal virilization often leading to male gender role adoption. High T/DHT ratio (>17) post-hCG.

Disorders of Androgen Action

• Androgen Insensitivity Syndrome (AIS): X-linked recessive AR mutations.
  • Complete AIS (CAIS): Female external genitalia, blind vaginal pouch, absent uterus (AMH still active). Normal breast development at puberty (testosterone aromatized to estrogen). Primary amenorrhea presentation.
  • Partial AIS (PAIS): Wide spectrum (Reifenstein syndrome). Perineoscrotal hypospadias, bifid scrotum, gynecomastia at puberty.

Disorders of AMH Action

• Persistent Müllerian Duct Syndrome (PMDS): Mutations in AMH or AMHR2. Fully virilized male with bilateral cryptorchidism and retained uterus/fallopian tubes.

Sex Chromosome DSD

• Mixed Gonadal Dysgenesis (45,X/46,XY):
  • Extreme phenotypic variability.
  • Usually unilateral testis and contralateral streak gonad.
  • Müllerian structures present.
  • High risk of germ cell neoplasia (gonadoblastoma).

Syndromic Associations of DSD

Diagnostic Evaluation of DSD

Clinical History

• Family history of consanguinity, neonatal deaths (suggests CAH).
• Family history of infertility, amenorrhea, or delayed puberty (suggests X-linked AIS or enzymatic defect).
• Maternal virilization during pregnancy (aromatase deficiency, luteoma).
• Maternal drug ingestion (progestins, androgens).

Physical Examination

• General Exam: Dysmorphic features (syndromic DSD), hyperpigmentation (CAH/ACTH excess).
• Gonadal Palpation: Critical step. Bilateral palpable gonads below the inguinal ring are almost always testes (virtually excludes 46,XX CAH). Unilateral gonad suggests mixed gonadal dysgenesis or ovotesticular DSD.
• Phallic Assessment: Measure stretched penile length. Normal full-term male is >2.5 cm. Micropenis <2.5 cm. Assess chordee and hypospadias location.
• Labioscrotal Fusion: Prader staging (I to V).
• Anogenital Distance (AGD): Biomarker of prenatal androgen exposure.

Laboratory Investigations

• Tier 1 (Immediate):
  • Rapid karyotype and FISH (X and Y specific probes).
  • Serum electrolytes, glucose, blood gas (evaluate for salt-wasting/adrenal crisis).
  • Serum 17-OHP (drawn after 48 hours of life to minimize false positives, rules out 21-OHD).
• Tier 2 (Hormonal Profiling):
  • LH, FSH, Testosterone, DHT, Androstenedione, DHEA, AMH.
  • AMH serves as biomarker of Sertoli cell presence/function.
  • hCG Stimulation Test: Assesses Leydig cell capacity to synthesize testosterone and differentiates enzymatic blocks (e.g., T/DHT ratio for 5α-reductase deficiency, Androstenedione/T ratio for 17β-HSD3).
• Genetic Diagnostics:
  • Microarray (CGH), specific DSD gene panels, or whole exome sequencing (WES) to identify WT1, SF1, SOX9, SRY mutations.

Imaging and Surgical Evaluation

• Pelvic/Abdominal Ultrasound: Identifies presence/absence of uterus, fallopian tubes, and locating intra-abdominal gonads.
• Genitogram / Voiding Cystourethrogram: Determines level of vaginal fusion with urogenital sinus (critical for surgical planning).
• Laparoscopy & Gonadal Biopsy: Indicated for complex anatomical clarification and defining ovotesticular DSD versus dysgenetic testes.

Multidisciplinary Management & Therapeutic Strategies

The DSD Team & Psychosocial Support

• Composition: Pediatric endocrinologist, urologist/surgeon, geneticist, neonatologist, psychologist.
• Communication: Avoid gender-specific pronouns initially (use "your baby"). Utilize neutral terms ("gonads" instead of testes/ovaries).
• Reassure parents that condition is manageable and not their fault. Provide extensive psychological support to mitigate parental PTSD and anxiety.

Sex of Rearing Assignment

• Dictated by fertility potential, surgical feasibility, anatomical status, and natural history of the specific diagnosis.
• 46,XX CAH: Highly fertile. Almost universally reared female, regardless of degree of virilization.
• CAIS: Assigned and reared female due to complete phenotypic feminization.
• PAIS: Challenging. Depends on clinical response to exogenous testosterone. High dissatisfaction rate (25%) regardless of assignment.
• 5α-Reductase & 17β-HSD3 Deficiencies: Profound pubertal virilization. Reared male if diagnosed early, as many assigned female will spontaneously transition to male identity at puberty.

Medical Management

• CAH: Immediate physiological glucocorticoid (hydrocortisone) to suppress ACTH/androgens, plus mineralocorticoid (fludrocortisone) and salt supplementation for salt-wasters.
• Hypogonadism: Sex steroid replacement (estrogen or testosterone) instituted at expected age of puberty in incremental doses.
• Micropenis: Short course of low-dose intramuscular testosterone (e.g., 25 mg monthly x 3) in infancy to stimulate penile growth prior to surgery.

Surgical Interventions & Malignancy Risk

• Genitoplasty: Timing is highly controversial. Trend towards shared decision-making and delaying elective, irreversible surgeries until the patient can provide informed consent.
• Females (CAH): Vaginoplasty/clitoroplasty historically done early, but increasingly deferred to minimize compromised genital sensitivity and stenosis. Early surgery reserved for severe urogenital sinus risking urinary retention.
• Males (Hypospadias/Chordee): Multi-stage repair.
• Gonadectomy: Mandatory if Y-chromosome material (TSPY gene) is present in a dysgenetic streak gonad or intra-abdominal testis (e.g., Mixed Gonadal Dysgenesis, Swyer syndrome) due to 15-40% risk of gonadoblastoma/dysgerminoma.
  • In CAIS, gonadectomy is frequently deferred until post-puberty to allow spontaneous estrogen-induced breast development (aromatized from testicular testosterone).

Long-Term Outcomes & Prognosis

• Fertility: Excellent in optimally treated CAH. Usually absent in mixed gonadal dysgenesis, complete androgen insensitivity, and XX males. Assisted reproductive techniques (ART) such as microTESE increasingly successful.
• Bone Health: Patients with gonadal failure (e.g., Turner syndrome, CAIS post-gonadectomy) require optimal HRT to prevent severe osteopenia.
• Transition of Care: Structured handover to adult endocrinology and urology is imperative for ongoing hormone management, sexual function surveillance, and psychosocial support.